Diapositive 1

1299 / 1674

Premenopausal women with
hormone receptor–positive,
HER2-negative disease and high
recurrence
risk, as defined by
clinicopathologic
characteristics, may experience
improvement of 10% to
15% in 5-year BCFI with
exemestane plus OFS versus
tamoxifen alone.